Transforming cell therapies with dual CAR strategies

CAR T-cell therapy has shown some remarkable success including several market approvals. However, challenges remain such as antigen escape, tumor heterogeneity, and solid tumors.

Dual CAR T-cell therapy has emerged as an innovative strategy that has the potential to overcome these limitations.

In this white paper, you will learn about:

• The evolution of CAR design
• The potential advantages of dual CAR constructs
• Manufacturing challenges associated with their clinical translation
• How Revvity’s LentiBOOST™ transduction enhancer and BioLegend’s Cell-Vive™ reagents can help to optimize manufacturing processes

LentiBOOST Pharma-Grade: For research use only. Not for use in diagnostic procedures.
LentiBOOST GMP Grade: Not for diagnostic use. Other applications must be authorized by a license from Revvity.
Cell-Vive™ GMP: For research use only. Not for use in diagnostic procedures.